Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Myeloid 1

Conditions

Neoplasm of Uncertain Malignant Potential 1

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × peginterferon alfa-2a × Other solid neoplasm × Clear all
NCT00253474 2012-03-29

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
36 enrolled
Other solid neoplasm

Neoplasm of Uncertain Malignant Potential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡